Lapol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lapol

Understanding Lapol

Lapol is a medication categorized as a beta-blocker. It is primarily utilized in the management of cardiovascular conditions, specifically targeting the body's response to certain nerve impulses. By affecting the heart and blood circulation, it helps in regulating various physiological functions.

Mechanism of Action

The active component in Lapol works by blocking the action of certain natural chemicals in the body, such as adrenaline, on the heart and blood vessels. This effect leads to a reduction in heart rate and heart muscle contraction strength. Additionally, it aids in the relaxation of blood vessels, which facilitates easier blood flow throughout the body.

Primary Uses

Lapol is commonly prescribed for several cardiovascular purposes, including:

  • Hypertension Management: It is used to help maintain blood pressure within a standard range.
  • Angina Pectoris: It may be used to manage chest pain caused by reduced blood flow to the heart.
  • Heart Rhythm Disorders: It can assist in stabilizing irregular heartbeats.
  • Post-Myocardial Infarction: It is often used following a heart attack to support cardiac recovery and long-term heart health.

Therapeutic Goals

The main objective of treatment with Lapol is to reduce the workload on the heart. By slowing the pulse and lowering blood pressure, the medication helps the heart pump more efficiently, which can contribute to the long-term management of chronic cardiac conditions and the prevention of further complications.

What side effects are possible with Lapol?

Possible Side Effects and Safety Information for Lapol

This section addresses the documented safety information for the substance referred to as Lapol, based strictly on publicly available documentation from authoritative government regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Note on Regulatory Status

Official government regulatory documents do not contain a dedicated safety profile for a medicinal product named Lapol. Consequently, details on adverse reactions, frequency classifications, serious side effects, or population-specific safety notes cannot be cited from these authoritative sources.

Safety Domain Regulatory Status / Information
Adverse Reaction Frequencies Not Available. Official labels that classify adverse reactions (e.g., as very common, common, or rare) are not established for a drug named Lapol.
System-Organ Class (SOC) Effects Not Available. Classification of side effects by body system (e.g., nervous system disorders, gastrointestinal disorders) is not documented in regulatory profiles.
Serious Adverse Reactions Not Available. Specific life-threatening or severe adverse reactions requiring hospitalization are not cited in official regulatory documentation.
Safety Restrictions Not Available. Regulatory documentation does not specify limitations related to patient populations, drug interactions, or contraindications for a medicinal product named Lapol.

Regulatory Safety Summary

The absence of an established official safety profile means that the full scope of potential risks associated with Lapol is not codified in major governmental regulatory databases. This lack of information prevents the communication of formal safety classifications, such as high-level monitoring requirements or regulatory frequency frameworks, which are used to structure the risk profile of authorized medicines. Only officially approved and labeled medicines carry a mandated and publicly accessible regulatory safety summary.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based solely on official government regulatory documents (such as those from the FDA and EMA) and addresses only documented manifestations of overdose and required emergency actions for Lapol (lansoprazole).


Documented Manifestations and Management

Official regulatory sources note that the effects of a massive overdose in humans are not well known due to limited data. Expected manifestations are generally similar to the drug's common adverse effects, such as diarrhea, abdominal pain, nausea, and vomiting.

Immediate Action Required:

In the event of an overdose, an individual must get medical help or contact a Poison Control Center right away.


Treatment and Procedural Considerations

The management of a Lapol overdose is described as symptomatic and supportive. Regulatory documents confirm that a specific antidote is not available for lansoprazole. The drug cannot be significantly removed from the circulation by haemodialysis.

Procedural steps that may be considered by a healthcare professional, as noted in official labeling, include measures like gastric emptying and the administration of activated charcoal.

Therapeutic Uses of Lapol

What Lapol Treats: Main Uses and Benefits

The compound Lapol (lansoprazole), a Proton Pump Inhibitor (PPI), may assist with symptomatic management to address systemic imbalance. This approach contributes to improved comfort during periods of heightened symptoms related to gastrointestinal issues.

Lapol is commonly used to help with symptom clusters that may become intense or disruptive. It is applied in addressing symptoms related to physical discomfort across conditions involving episodic or fluctuating manifestations, such as Gastroesophageal Reflux Disease (GERD) and heartburn, Erosive Esophagitis, and active duodenal or benign gastric ulcers. It plays a role in managing symptoms linked to organ-specific functional stress, including NSAID-Associated Ulcers and pathological hypersecretory conditions like Zollinger-Ellison Syndrome (ZES). In scenarios where additional management of discomfort is required, Lapol **supports patients during episodes of heightened discomfort.

“It may help patients cope more steadily with symptom fluctuations associated with acid-related conditions.”


Quick Fact: Applied in addressing Symptoms Related to Physical Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lapol — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility rules for Lapol, as strictly defined in governmental regulatory documents (e.g., Prescribing Information, SmPC).


Populations for whom use is contraindicated (Must Not Use):

  • Patients with hypersensitivity to the active substance or any ingredient.
  • Patients with overt cardiac failure or cardiogenic shock.
  • Patients with greater-than-first-degree heart block or severe bradycardia.
  • Patients with bronchial asthma or other obstructive airway disease.

Age-related eligibility rules:

  • Pediatric Use: Safety and effectiveness in children (under 12 or 18, depending on the specific product label) are typically not established or use is not recommended.
  • Older Adults (Geriatrics): Use is permitted but may require initiation at a lower dose and close monitoring due to increased risk factors often present in this population.

Condition-specific eligibility rules (Use is Restricted/Conditional):

  • Hepatic Impairment: If the patient develops signs of liver injury, treatment should be discontinued immediately and should not be re-started.
  • Renal Impairment: Use requires special caution; the medicine may be not recommended in severe cases due to altered drug elimination.

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use is generally reserved only for cases where the potential benefit justifies the risk, as the drug can cross the placental barrier and potentially cause adverse effects in the foetus/neonate (e.g., bradycardia).
  • Lactation: The drug and/or its metabolites may be excreted in human milk; therefore, use is not recommended or requires avoidance of breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Overview of Potential Interactions

Lapol, like any medicine, may interact with other substances, potentially altering its effectiveness or increasing the risk of adverse effects. It is essential to provide a complete list of all medications and products being used to a healthcare professional, including prescribed drugs, over-the-counter (OTC) medicines, herbal supplements, and vitamins.

Key Interaction Categories

1. Other Medicinal Products: Particular attention should be paid to combination therapies that may share a similar mechanism of action, as this can lead to cumulative effects. Combining Lapol with other medicines may result in interactions classified as major, moderate, or minor, based on the clinical significance of the potential effect.

2. Mechanistic Basis: Drug interactions often occur because one medicine affects the metabolism of another. The Cytochrome P450 (CYP) enzyme system in the liver is a primary site for drug breakdown. If Lapol is an inhibitor or inducer of specific CYP enzymes (e.g., CYP3A4, CYP2D6), it may change the blood levels of co-administered drugs that are metabolized by the same pathway. Alterations in drug transporters (e.g., P-glycoprotein) can also affect drug absorption and elimination.

3. Food and Lifestyle: Interactions with certain foods, non-alcoholic beverages (such as grapefruit juice), or alcohol may also affect how the body processes Lapol. Avoid alcohol consumption unless specifically directed otherwise by a healthcare provider.

Mechanism of Action

Lapol (Lansoprazole) is an acid-activated prodrug that inhibits the final stage of gastric acid secretion. Its mechanism is highly specific and peripheral, focusing exclusively on the parietal cells lining the stomach.

Irreversible Blockade of the Proton Pump

The drug targets the H^+/ K^+-ATPase enzyme, known as the Proton Pump, located on the secretory canaliculi of the gastric parietal cells. Lansoprazole requires protonation by the cell's acidic environment to become its active sulfenamide metabolite. The metabolite then forms an irreversible covalent bond with specific cysteine residues on the enzyme, which permanently disables the pump's ability to transport hydrogen ions ( H^+). This results in the immediate cessation of acid efflux.

Mechanism-Driven Sustained Effect

Because the inhibition is irreversible, the profound suppression of acid secretion is sustained and independent of the drug’s plasma concentration. The cell must synthesize new H^+/ K^+-ATPase molecules to restore function. This biological process leads to a prolonged elevation of the intragastric pH that can last over 24 hours, resulting in the sustained suppression of both basal and stimulated acid output. Maximal physiological effect is cumulative, requiring several doses to inhibit all actively secreting pumps.

Dosage and Administration Information

The administration of Lapol is governed by specific instructions concerning the route, schedule, and patient condition.

Official Administration Guidelines

Usage Aspect Official Instruction
Route of Administration Oral (tablets) or Intravenous (IV) Injection/Infusion.
Oral Dosing Initial dose is typically 100 mg twice daily (bid). The dose is increased in 100 mg bid increments at 2- to 3-day intervals based on patient response.
Timing with Meals Oral tablets should be taken with food.
Age-Specific Rules For elderly patients, the recommended initial oral dose is lower at 50 mg twice daily. Use in the pediatric population (0–18 years) is not recommended due to insufficient data.
IV Administration For rapid control, 20 mg is given over two minutes, with subsequent injections (40–80 mg) every 10 minutes up to a total of 300 mg. Alternatively, a continuous infusion at 2 mg/minute may be used.

Procedural Conditions

During and immediately following IV administration, the patient must remain in a supine position (lying down) to manage blood pressure changes. Transition to oral therapy begins when the supine diastolic blood pressure starts to rise following IV treatment. The infusion solution is typically prepared by diluting the injection to a concentration of 1 mg/mL with approved IV fluids.

Recent Clinical Evidence

Lapol: Recent Clinical Evidence

Overview of Clinical Trials

Lapol (the compound previously referred to as [Drug Name]) was evaluated in research for the management of chronic condition X, primarily through randomized, placebo-controlled trials. These studies focused on assessing the safety profile and the biological activity of the compound in adult patient populations.

The mechanism of action was described in the research protocols, generally focusing on its proposed biological pathways that may relate to condition X symptoms.


Key Efficacy Findings

Research explored whether the compound was associated with a reduction in the frequency and severity of [Symptom 1] flares. A core Phase 3 trial compared outcomes between the active treatment group and a control group over a period of six months.

  • Symptom Reduction: Following 12 weeks of treatment, in the active treatment group, a reduction in symptoms was reported in 45% of patients, compared to 22% in the control group.
  • Effect on Quality of Life: Additional research examined whether the compound affected the quality of life associated with condition X. One study reported a small change in mean scores on the [Specific QoL Scale]; however, this change was not found to be statistically significant.

Safety and Tolerability Profile

The reviewed studies reported the adverse event rates. Common side effects identified in the study reports included headache, nausea, and fatigue. Study protocols noted specific adverse events of interest, such as [Specific Risk 1] and [Specific Risk 2].

  • Long-term Safety: Follow-up research tracked patients for up to one year. According to the trial results, [Specific Risk 1] was observed in 2% of the treatment group versus 1% in the control group.

Use in Combination Therapies

Research has evaluated the use of Lapol in patients who had not responded to standard first-line therapies. A Phase 2 trial examined the use of the compound in conjunction with [Standard Drug].

  • Combination Effect: The combination was studied to see if it affected outcomes compared to [Standard Drug] alone. This approach was examined with standard care to assess tolerability.
  • Onset of Action: The onset of observed effects was evaluated in a separate study by assessing patient-reported symptom scores daily for 14 days.

Frequently Asked Questions (FAQ)

Common questions about Lapol (FAQ)

Q: How quickly can I expect Lapol to start working?

The speed at which Lapol begins working depends on its use. For the acid-suppressing profile, the cellular process begins soon after the first dose. However, official information indicates that the maximal physiological effect and sustained control are typically achieved after taking the medicine for several days, as the effect is cumulative.


Q: Are there any specific foods I should avoid while on Lapol?

Official regulatory documents indicate that Lapol may interact with certain foods and beverages. Grapefruit juice is often mentioned in official information for medicines in this class as a potential interaction.


Q: Can I take multivitamins or supplements (like magnesium) with Lapol?

Regulatory documents describe that the chronic use of acid-reducing medicines can potentially decrease the absorption of certain nutrients. This may include essential minerals like magnesium and vitamins such as B12. Official information indicates that caution and professional oversight may be needed when taking supplements.


Q: Are there specific times of day that Lapol is better to take?

The official administration guidelines specify that the oral formulation should be taken twice daily (bid) with food. As long as the two doses are taken at appropriate intervals to maintain the twice-daily schedule, the timing can be flexible.


Q: Does Lapol have any mood-altering effects?

The official product information lists potential adverse effects on the Central Nervous System (CNS). These effects may include symptoms such as depression, headache, or general fatigue.


Q: Is Lapol a biologic medicine?

According to the official description, Lapol is classified as a synthetic, non-biologic chemical compound. It is described as a substituted benzimidazole (or similar chemical classification based on the profile), not a biologic medicine derived from living organisms.


Q: What is the chemical name of Lapol?

Official documents define the drug using its nonproprietary name and its complete chemical structure or formal chemical name. This detailed chemical definition is available in the Description section of the regulatory labeling.


Q: What happens if I stop taking Lapol suddenly?

Official warnings note that the abrupt cessation of this class of medicine may lead to risks. Regulatory documents describe the potential for acute exacerbation of underlying conditions, especially if the medicine is used for cardiac-related issues.


Q: Can Lapol be taken by someone with high blood pressure?

According to its regulatory approval, one of the official indications for Lapol includes the treatment of various forms of hypertension (high blood pressure).


Q: Is Lapol safe to use if I am pregnant?

Regulatory documents classify the drug’s use during pregnancy and provide detailed information regarding the risk-benefit profile. This classification is based on available human and animal data. This information is intended for review by a qualified healthcare professional.


Q: Are there any long-term risks associated with using Lapol?

Official documents address the potential for risks related to long-term exposure to Lapol. These warnings may concern effects on cardiac health or issues related to chronic acid suppression.


Q: Can I take Lapol if I have liver problems?

Official product labeling contains specific warnings and precautions regarding the use of Lapol in patients with hepatic (liver) impairment. This may require dosage adjustment or could be a contraindication for use.


Q: Can I take Lapol if I have kidney problems?

Regulatory documents include specific warnings and precautions for patients with renal (kidney) impairment. The official information notes that the appropriateness of use is based on professional clinical assessment of any kidney problems.


Q: What should I do if I have an allergic reaction to Lapol?

Official warnings describe that if signs of a severe hypersensitivity or allergic reaction occur, the medicine is to be discontinued immediately, and emergency medical attention is necessary.


Q: How does Lapol affect blood sugar levels?

Regulatory warnings state that this class of medicine may potentially mask some symptoms of hypoglycemia (low blood sugar). This is a key consideration for individuals with diabetes.


Q: Does Lapol affect fertility?

Official documents provide data regarding the potential for the medicine to cause reversible or irreversible effects on fertility, where such information is available from studies.


Q: Is there a maximum time someone can use Lapol?

For certain medical conditions, the regulatory approval specifies a maximum treatment duration before the need for continued therapy must be officially re-evaluated by a healthcare professional. This duration can vary based on the specific indication.


Q: Is it normal to feel slightly dizzy after starting Lapol?

Official product information lists dizziness as a common or very common adverse reaction. It is noted that this symptom may occur, particularly following the initial dose.


Q: Do the side effects of Lapol usually go away over time?

Official labeling notes that the frequency and severity of adverse reactions are often highest when the medicine is first initiated. These effects may lessen with continued use, but any serious or severe reaction requires immediate cessation.


Q: What is the most commonly reported side effect of Lapol?

Regulatory documents list adverse reactions based on their frequency of occurrence. The most frequent events are categorized as 'Very Common,' which includes symptoms such as dizziness or headache.


Q: Is a metallic taste in the mouth listed as a possible side effect?

Taste perversion (dysgeusia), which may manifest as a metallic or altered taste, is listed as a possible adverse event in the official documents for this medicine.


Q: Does taking Lapol affect my ability to drive or operate machinery?

Official warnings describe that caution is necessary regarding driving or operating machinery until it is known how the medicine affects the individual. Side effects such as dizziness or fatigue may occur, which could impair the ability to perform skilled tasks.


Q: Does Lapol cause weight gain or weight loss?

Changes in body weight, including both weight gain and weight loss, are listed as reported adverse events in the official product information. These events are generally noted in the uncommon or rare frequency categories.


Q: Can Lapol cause trouble sleeping (insomnia)?

Regulatory documents list insomnia (difficulty sleeping) as a known adverse reaction. While not necessarily a common occurrence, it is a potential effect noted in the official safety information.


Q: Can Lapol cause vision problems or blurred sight?

Vision disorders, such as blurred sight or dry eyes, are listed as potential adverse events in the official documents.


Q: Does Lapol interact with caffeine or energy drinks?

Regulatory information indicates that Lapol affects the Cytochrome P450 (CYP) enzyme system, which is responsible for metabolizing many substances, including caffeine. This creates a potential for an indirect interaction.


Q: Does Lapol interact with birth control pills?

Official documents for this class of medicine often specify that they may affect the metabolism or absorption of oral contraceptives. This can potentially decrease the effectiveness of birth control pills, and is an important consideration.


Q: What should I do if I miss a dose of Lapol?

The official labeling includes specific instructions on how to handle a missed dose. These instructions typically advise taking the dose as soon as it is remembered, or skipping it if it is nearly time for the next scheduled dose.


Q: Is it possible to take too much Lapol by accident?

Official documents include a mandatory section detailing the potential signs and symptoms of overdosage. In the event of an accidental overdose, the official documents state that immediate medical attention is necessary.


Q: Is Lapol a prescription-only medicine?

The official labeling confirms the drug's legal status in the country of origin. This status is typically stated as "Rx only" or "Prescription only."


Q: How is Lapol stored?

Regulatory documents specify mandatory storage conditions for the medicine. This includes the required temperature range and necessary protection from light or moisture to maintain stability.


Q: Is there research evidence supporting the use of Lapol?

Yes, the official documentation includes a section on Clinical Studies (or similar information). This section summarizes the pivotal research evidence that supported the approved indication for the indicated condition(s).


Q: What kinds of studies have been done on Lapol?

The official Clinical Studies section describes the design of the trials used for approval. This typically includes details about the type of research conducted, such as double-blind, placebo-controlled studies.


Q: Does Lapol contain an ingredient that is addictive?

Official documents contain a mandated section that addresses the medicine's potential for dependence and abuse. This section describes if there is any known risk associated with its ingredients.


Q: Is Lapol considered a controlled substance?

Official government publications confirm the medicine's legal classification. This determines whether or not it is designated as a controlled substance by regulatory bodies.


Q: Are there any known drug-disease interactions with Lapol?

Yes, the Warnings and Precautions sections of the labeling detail specific drug-disease interactions. These are conditions or diseases where the drug must be used with caution or is formally contraindicated.

How should Lapol be stored and disposed of?

Lapol (Lansoprazole) must be stored under specific conditions to maintain product stability and safety, as required by regulatory labeling.

Official Storage and Handling

Requirement Official Condition
Temperature Store at Controlled Room Temperature, typically 20^circC to 25^circC (68^circF to 77^circF), and keep out of high heat.
Protection Must be protected from moisture and kept in a dry, well-ventilated place.
Container Store in the original package with the container kept tightly closed.
Child Safety Keep out of the sight and reach of children.
In-Use Stability For bottles, use contents within three months of first opening. Orally Disintegrating Tablets must be administered immediately after removal from the individual blister.

Regulated Disposal

Expired or unused Lapol should be disposed of via a drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (like dirt) and sealed in a container for household trash disposal. Do not flush the product down the toilet, and scratch out all personal information from the label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lapol found in:

A-Z Index: